Humana Inc. (HUM) Shares Sold by Scout Investments Inc.

Scout Investments Inc. lessened its holdings in shares of Humana Inc. (NYSE:HUM) by 11.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 61,361 shares of the insurance provider’s stock after selling 7,910 shares during the period. Scout Investments Inc.’s holdings in Humana were worth $14,765,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in HUM. BlackRock Inc. grew its holdings in shares of Humana by 2,281.7% during the first quarter. BlackRock Inc. now owns 12,387,144 shares of the insurance provider’s stock worth $2,553,487,000 after purchasing an additional 11,867,056 shares during the last quarter. FMR LLC boosted its holdings in Humana by 57.9% in the first quarter. FMR LLC now owns 5,050,853 shares of the insurance provider’s stock valued at $1,041,184,000 after acquiring an additional 1,851,197 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in Humana by 84.3% in the first quarter. Renaissance Technologies LLC now owns 2,691,700 shares of the insurance provider’s stock valued at $554,867,000 after acquiring an additional 1,231,400 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Humana by 2,651.1% in the first quarter. Wellington Management Group LLP now owns 775,755 shares of the insurance provider’s stock valued at $159,915,000 after acquiring an additional 747,557 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Humana by 413.8% in the first quarter. AQR Capital Management LLC now owns 736,019 shares of the insurance provider’s stock valued at $151,723,000 after acquiring an additional 592,772 shares during the last quarter. Institutional investors own 95.14% of the company’s stock.

Humana Inc. (HUM) opened at 249.28 on Friday. Humana Inc. has a 1-year low of $163.50 and a 1-year high of $259.76. The firm has a 50-day moving average price of $250.25 and a 200-day moving average price of $231.50. The company has a market capitalization of $36.03 billion, a P/E ratio of 20.51 and a beta of 0.87.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, August 2nd. The insurance provider reported $3.49 EPS for the quarter, topping the consensus estimate of $3.08 by $0.41. The firm had revenue of $13.53 billion during the quarter, compared to the consensus estimate of $13.61 billion. Humana had a return on equity of 15.85% and a net margin of 3.37%. During the same period in the prior year, the business posted $2.30 earnings per share. On average, analysts forecast that Humana Inc. will post $11.55 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Investors of record on Tuesday, August 29th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.64%. The ex-dividend date of this dividend is Thursday, September 28th. Humana’s payout ratio is 13.06%.

Several equities analysts recently issued reports on HUM shares. Citigroup Inc. started coverage on Humana in a report on Wednesday, June 28th. They issued a “buy” rating and a $275.00 price target on the stock. BidaskClub cut Humana from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Zacks Investment Research upgraded Humana from a “hold” rating to a “buy” rating and set a $257.00 price target on the stock in a report on Thursday, May 25th. Argus upgraded Humana from a “hold” rating to a “buy” rating and set a $260.00 target price on the stock in a report on Friday, June 9th. Finally, Bank of America Corporation raised their target price on Humana from $270.00 to $275.00 and gave the stock a “buy” rating in a report on Friday, July 14th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $244.35.

TRADEMARK VIOLATION WARNING: This story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was copied illegally and reposted in violation of US and international copyright legislation. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/09/16/scout-investments-inc-has-14-77-million-stake-in-humana-inc-hum.html.

In other Humana news, insider Elizabeth D. Bierbower sold 9,786 shares of the stock in a transaction on Friday, September 1st. The stock was sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the completion of the transaction, the insider now directly owns 18,042 shares of the company’s stock, valued at $4,672,878. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Brian P. Leclaire sold 4,971 shares of the stock in a transaction on Wednesday, June 28th. The shares were sold at an average price of $240.00, for a total value of $1,193,040.00. Following the transaction, the senior vice president now directly owns 14,258 shares of the company’s stock, valued at $3,421,920. The disclosure for this sale can be found here. Insiders have sold 60,566 shares of company stock valued at $15,326,746 over the last ninety days. 0.80% of the stock is currently owned by company insiders.

Humana Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Institutional Ownership by Quarter for Humana (NYSE:HUM)




Receive News & Ratings for Humana Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Humana Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply